Companies

Forbion’s Sander Slootweg looks back over the company’s most successful year so far, and looks ahead at likely market and therapy area trends for 2024.

Obesity drug pemvidutide looks better at nearly a year than it did at six months, but still lags rivals Wegovy and Zepbound.

Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.

The investment wings of big biopharma are taking part in a larger proportion of VC deals than ever before.

Hopes are that the impact of the US FDA’s investigation into a small number of T-cell malignancies associated with CAR-T therapies will be small since the benefit/risk profile still looks sound.

Big pharmaceutical oncology franchise sales generally grew in the third quarter of 2023, but some were transitioning through loss of exclusivity and others were not being helped by their most innovative therapies.

UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.

SpringWorks’ gamma secretase inhibitor will be available soon for adults at any stage of treatment for desmoid tumors with a list price of $29,000 for a 30-day supply. 

Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.

Heart disease seems impervious to cell therapy approaches. Is biomarker stratification the answer?

GSK will talk to regulators about bringing Blenrep back in earlier-stage myeloma patients, likely arguing that its convenience is greater than for CAR-T and carries a lower infection risk than bispecifics.

A second pivotal hit positions Sanofi and Regeneron’s antibody for approval in COPD – but other biologics are coming fast.

After a year of hype around generative AI, the question is can it deliver productivity wins for biopharma? Consultants at BCG give insights into successes and failures of early projects and emphasize that putting people first is key to success.

Syncona has stepped in to save Freeline and give it more time to prove the value of FLT201, its early-stage Gaucher’s disease gene therapy.

Quotient Therapeutics is the fifth new start-up unveiled by Flagship this year, and will be co-located in the US and UK to tap into leading academic genomic expertise.

China's research-based pharma companies reported mixed third-quarter results for their anti-PD-1 antibodies, BTK and PARP inhibitors amid broader challenges including an ongoing government-led anti-corruption campaign.